Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

Lombardo is as about as uninspiring speaker as one can imagine. To the extent that finding investors depends on telling a compelling story, this guy is a LOSER, in capitals.

Substantively, nothing new in his presentation as far as I can tell. The presentation again makes a plain as day how much this company needs significant additional investment dollars to pursue its therapies. Revenues -- except what might come through the current agreements (and I'm not sure how much/ how soon those current partnership revenues could be) -- are surely no sooner than 2020, even with timely EU approval, which looks like, at best, late 2018/ early 2019. I have always been figuring mid-2019 and then 6-12 months ramp to actual sales.

While timing and need for significant funding has been obvious all along, none of this concerned me when DOC was CEO because I had confidence in his ability to raise funds at good prices in a timely way. He had done so all along. His firing has severely confused my thinking as to whether I should continue to hold ADXS or move on because so far I do not have confidence in Lombardo -- he has done nothing to suggest he will be effective raising money and keeping the programs on track.

Sigh.